Redx Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Redx Pharma şirketinin toplam hissedar öz sermayesi £3.4M ve toplam borcu £15.7M olup, bu da borç-öz sermaye oranını 468.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla £25.6M ve £22.3M dir.

Anahtar bilgiler

468.9%

Borç/özkaynak oranı

UK£15.73m

Borç

Faiz karşılama oranı	n/a
Nakit	UK£18.09m
Eşitlik	UK£3.36m
Toplam yükümlülükler	UK£22.28m
Toplam varlıklar	UK£25.64m

Son finansal sağlık güncellemeleri

Does Redx Pharma (LON:REDX) Have A Healthy Balance Sheet?

Aug 22

Is Redx Pharma (LON:REDX) Using Too Much Debt?

May 22

Recent updates

Does Redx Pharma (LON:REDX) Have A Healthy Balance Sheet?

Aug 22

Is Redx Pharma (LON:REDX) Using Too Much Debt?

May 22

Bullish: Analysts Just Made A Significant Upgrade To Their Redx Pharma Plc (LON:REDX) Forecasts

Jul 09

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: REDX 'nin kısa vadeli varlıkları ( £23.3M ) kısa vadeli yükümlülüklerini ( £21.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: REDX şirketinin kısa vadeli varlıkları ( £23.3M ) uzun vadeli yükümlülüklerini ( £1.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: REDX şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: REDX şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 468.9% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: REDX son raporlanan serbest nakit akışına göre 6 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: REDX serbest nakit akışı tahminlerine göre 5 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.

Redx Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Redx Pharma Provides Update on AIM Delisting

Does Redx Pharma (LON:REDX) Have A Healthy Balance Sheet?

Is Redx Pharma (LON:REDX) Using Too Much Debt?

Recent updates

Redx Pharma Plc Reports Encouraging Zamaporvint (RXC004) Phase 2 Combination Data in MSS mCRC at ESMO GI Congress

Redx to Present Zamaporvint Phase2 Data At Esmo Gi

Redx to Present Preclinical Data on RXC008 in an Oral Presentation at ECM Congress

Redx Pharma Provides Update on AIM Delisting

New major risk - Share price stability

Consensus EPS estimates upgraded to UK£0.062 loss

Redx Announces That First Participant Dosed in Phase 1 Trial of RXC008

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Redx Pharma Plc, Annual General Meeting, Mar 14, 2024

New minor risk - Share price stability

New minor risk - Market cap size

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Redx Pharma Plc to Report Fiscal Year 2023 Results on Dec 15, 2023

New minor risk - Financial data availability

New minor risk - Shareholder dilution

Redx Pharma plc to Present Preclinical Data on RXC009, A Selective Discoidin Domain Receptor 1 Inhibitor

Redx Pharma Plc has completed a Follow-on Equity Offering in the amount of £14.059359 million.

Redx Pharma plc Appoints Joseph Anderson as Non-Executive Director

Redx Pharma Plc Announces Executive Changes

Does Redx Pharma (LON:REDX) Have A Healthy Balance Sheet?

Redx Pharma plc Zelasudil Receives FDA Orphan Drug Designation

New minor risk - Market cap size

Redx Pharma Plc Announces Directorate Changes

Is Redx Pharma (LON:REDX) Using Too Much Debt?

Price target decreased by 9.9% to UK£1.32

First half 2023 earnings released: UK£0.062 loss per share (vs UK£0.035 loss in 1H 2022)

Redx Pharma Plc's Discovery of Pirtobrutinib Recognised with Unveiling of Commemorative Plaque At Alderley Park

Redx Pharma Plc Presents Preclinical Efficacy Data for RXC007 Showing Significant Results in Cancer-Associated Fibrosis Models

Redx Pharma Plc to Report First Half, 2023 Results on May 17, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Redx Pharma Plc, Annual General Meeting, Mar 14, 2023

Redx Pharma Plc Provides Progress Updates on RXC007 Clinical Programme

Consensus revenue estimates increase by 15%, EPS downgraded

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Redx Pharma Plc to Report Q4, 2022 Results on Dec 20, 2022

High number of new directors

Redx Pharma plc to Present on Potential of RXC007 in Fibrotic Diseases at Antifibrotic Drug Discovery Meeting

Redx Pharma plc Announces First Patient Dosed in Phase 2a Trial for RXC007

Bullish: Analysts Just Made A Significant Upgrade To Their Redx Pharma Plc (LON:REDX) Forecasts

Consensus revenue estimates increase by 24%

Consensus revenue estimates increase by 31%

Redx Pharma Announces Two Presentations Were Delivered at the Inaugural Extracellular Matrix Pharmacology Congress in Copenhagen, 23-25 June

First half 2022 earnings released

Redx Pharma Plc to Report Q2, 2022 Results on Jun 23, 2022

Redx Pharma Plc has completed a Follow-on Equity Offering in the amount of £34.261864 million.

Price target increased to UK£1.70

High number of new directors

Redx Pharma Plc Presents Encouraging RXC004 Preclinical Data

Redx Pharma plc Announces Nomination of Clinical Development Candidate

Redx Pharma Plc Announces Committee Changes

Redx Pharma Plc, Annual General Meeting, Mar 08, 2022

High number of new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

First half 2021 earnings released: UK£0.053 loss per share (vs UK£0.027 loss in 1H 2020)

Non-Executive Chairman Iain Ross has left the company

Redx Pharma Announces First Subject Dosed in Phase 1 Study with Lead Fibrosis Candidate RXC007, a ROCK2 Selective Inhibitor

Redx Pharma Announce Mead Will Step Down from the Board

Redx Pharma plc Announces Search for A US Based Chief Financial Officer Has Been Initiated

Chief Medical Officer has left the company

New 90-day high: UK£0.68

Redx Pharma Plc, Annual General Meeting, Mar 02, 2021

Earnings beat expectations, revenue disappoints

Redx Pharma Plc to Report Fiscal Year 2020 Results on Jan 27, 2021

New 90-day low: UK£0.54

Redx Pharma plc Announces the Appointment of Jane Robertson as Chief Medical Officer, Effective 1 March 2021

New 90-day high: UK£0.68

New 90-day high - UK£0.60

Redmile Group, LLC completed the acquisition of remaining 54.5% stake in Redx Pharma Plc (AIM:REDX).

Redx Pharma Plc announced that it expects to receive £23.63877 million in funding from Sofinnova Partners SAS, Redmile Group, LLC

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço